Cantor Fitzgerald Lowers Earnings Estimates for MannKind

Key Points

• Cantor Fitzgerald has lowered its FY2026 earnings per share estimate for MannKind Corporation from $0.24 to $0.14, which is below the consensus estimate of $0.10.
• MannKind reported a quarterly earnings per share of $0.05, surpassing the expected $0.04, although its revenue of $76.53 million fell short of the projected $77.82 million.
• Despite mixed analyst ratings and a consensus price target of $9.71, the company has had significant institutional investment activity, including 200% increase in holdings by Quaker Wealth Management LLC during the second quarter.

MannKind Corporation (NASDAQ:MNKD - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2026 earnings per share estimates for MannKind in a research report issued to clients and investors on Thursday, August 7th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings of $0.14 per share for the year, down from their prior forecast of $0.24. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. The firm had revenue of $76.53 million during the quarter, compared to analyst estimates of $77.82 million. MannKind had a negative return on equity of 32.60% and a net margin of 10.87%. The company's revenue was up 5.7% on a year-over-year basis. During the same period last year, the company earned $0.05 earnings per share.

A number of other brokerages have also commented on MNKD. HC Wainwright upgraded MannKind to a "buy" rating and set a $9.00 price objective for the company in a research report on Wednesday, July 16th. Wall Street Zen lowered MannKind from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Royal Bank Of Canada decreased their target price on MannKind from $8.00 to $7.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, MannKind has a consensus rating of "Buy" and a consensus target price of $9.71.

MannKind Stock Up 7.0%

MNKD stock traded up $0.24 during midday trading on Friday, reaching $3.66. The stock had a trading volume of 4,568,174 shares, compared to its average volume of 2,378,573. The business has a fifty day simple moving average of $3.85 and a two-hundred day simple moving average of $4.60. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of 33.28 and a beta of 1.02. MannKind has a twelve month low of $3.38 and a twelve month high of $7.63.

Hedge Funds Weigh In On MannKind

Institutional investors have recently modified their holdings of the business. Quaker Wealth Management LLC lifted its stake in MannKind by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 7,000 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 14,000 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in MannKind by 1,379.2% in the 2nd quarter. Farther Finance Advisors LLC now owns 7,396 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 6,896 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in MannKind in the 4th quarter valued at approximately $37,000. Sumitomo Mitsui Trust Group Inc. bought a new stake in MannKind in the 2nd quarter valued at approximately $42,000. Finally, Master S Wealth Management Inc. bought a new stake in MannKind in the 2nd quarter valued at approximately $44,000. Institutional investors own 49.55% of the company's stock.

Insider Buying and Selling at MannKind

In other news, Director Steven B. Binder sold 75,367 shares of MannKind stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $3.94, for a total transaction of $296,945.98. Following the transaction, the director owned 830,508 shares in the company, valued at $3,272,201.52. The trade was a 8.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 153,875 shares of company stock worth $616,771. Insiders own 3.00% of the company's stock.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.